Skip to main content

Peer Review reports

From: Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Original Submission
11 Apr 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
19 Jul 2022 Reviewed Reviewer Report
25 Jul 2022 Reviewed Reviewer Report
17 Aug 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 4
17 Aug 2022 Submitted Manuscript version 4
22 Aug 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 5
22 Aug 2022 Submitted Manuscript version 5
25 Aug 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 6
25 Aug 2022 Submitted Manuscript version 6
21 Sep 2022 Reviewed Reviewer Report
23 Sep 2022 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
26 Sep 2022 Editorially accepted
28 Oct 2022 Article published 10.1186/s12885-022-10147-9

You can find further information about peer review here.

Back to article page